We use cookies for a better user experience. Read our Privacy Policy
I Agree
Sinusitis Treatment Market
Since sinus infection and COVID-19 have similar symptoms, there is a need to differentiate between the two. Stakeholders in the sinusitis treatment market are increasing awareness that coronavirus is associated with some of the striking symptoms such as dry cough, whereas sinus is linked with cough involving mucus. Other striking symptoms such as chills & aches and loss of smell or taste are helping people to distinguish between the two. As such, there is a lack of evidence whether COVID-19 causes sinusitis.
Due to the symptoms of sinus overlapping with that of COVID-19, stakeholders in the sinusitis treatment market are increasing awareness about telemedicine and e-health to reduce the load on healthcare professionals and minimize clinical visits. Digital consultations are growing rapidly among individuals living in urban cities. Stakeholders in the value chain are mapping future growth opportunities in telemedicine to increase its penetration in rural regions.
To know the scope of our report Get a Sample on Sinusitis Treatment Market
There is a growing need to re-think acute sinusitis treatment in adults. The current over-prescribing of antibiotics has led to an increase in drug-resistant pathogens, which has become an urgent public health threat in the U.S. This is leading to increased morbidity, mortality, and costs for patients & healthcare systems. Hence, companies in the sinusitis treatment market are increasing their R&D efforts to offer better alternative interventions to treat the symptoms of patients.
Antibiotics are predicted to dominate the second highest revenue among all treatment types in the market. However, current studies examining the efficacy of antibiotics for acute sinusitis have included generally healthy adults, and most have excluded patients with severe illnesses or co-existing conditions such as diabetes or pulmonary diseases. This has stressed on the importance of thorough research studies to improve clinical outcomes with the help of antibiotics in the sinusitis treatment market.
Get a glimpse of the in-depth analysis through our Report Brochure
The high prevalence of chronic rhinosinusitis (CRS) in the U.S. is creating lucrative revenue opportunities for companies in the sinusitis treatment market. Nasus Medical - a startup born out of Stanford Biodesign and now a Fogarty Institute Company is tapping incremental opportunities in the CRS treatment by developing a solution for improved intra-nasal drug delivery. Competitor companies are taking cues from such innovations to develop advanced devices that allow patients to treat themselves at home to minimize symptoms of chronic sinusitis in its early stages.
Since nasal steroid sprays are largely ineffective, given that they only reach the front most portion of the nasal cavity, companies in the sinusitis treatment market are increasing their R&D activities to develop devices that push past the nasal inflammation. These devices help to access the optimal anatomic target to make sprays more effective.
The unique nasal spray designs are a fast growing phenomenon in the global sinusitis treatment market. Innovators are gaining awareness that stakeholders need to go beyond drug innovations and focus more on ways to deliver it in hard to reach cavities of the patients’ sinuses. The Optinose XHANCE is gaining popularity for overcoming this challenge and developing a nasal spray that patients can use at the comfort of their home. Since the symptoms of acute sinusitis are fairly severe, and can be measured to the same magnitude of harm to a patient’s life as other chronic diseases, med-tech companies are innovating in new designs of nasal sprays.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Healthcare professionals and institutes are increasing efforts to educate people about the differentiating symptoms of sinus and COVID-19. The sinusitis treatment market is expected to reach US$ 4.5 Bn by 2031 and expand at a modest CAGR of ~4% during the assessment period. However, high-dose antibiotics and steroid pills lead to significant side effects. Hence, companies should develop devices that improve intra-nasal drug delivery using innovative devices and minimize side effects of antibiotics. Med-tech companies in the sinusitis treatment market are boosting their R&D capacities to develop devices that deploy bi-directional exhalation to allow fluticasone to move around the obstructions in the nasal cavity.
Sinusitis Treatment Market – Segmentation
TMR’s study on the global sinusitis treatment market includes information divided into five segments: disease type, treatment, route of administration, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global sinusitis treatment market are discussed in detail.
| Disease Type |
|
| Treatment |
|
| Route of Administration |
|
| Distribution Channel |
|
| Region |
|
The global sinusitis treatment market was worth US$ 2.9 Bn and is projected to reach a value of US$ 4.5 Bn by the end of 2031
Sinusitis treatment market is anticipated to grow at a CAGR of 4% during the forecast period
North America accounted for a major share of the global sinusitis treatment market
Sinusitis Treatment Market is driven by rise in prevalence of sinusitis, rise in invasive bacterial diseases and innovation in diagnosis of bacterial infections
Key players in the global sinusitis treatment market include Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy's Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca plc, Amneal Pharmaceuticals LLC, GlaxoSmithKline plc., Aurobindo Pharma, Hikma Pharmaceuticals plc, Wockhardt, and M
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sinusitis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sinusitis Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Clinical Trials & Regulatory Approvals Analysis
5.2. List of Brand / Product Approved
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.4. Technological Advancements
5.5. Disease Prevalence & Incidence
6. Global Sinusitis Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Antibiotics
6.3.1.1. Cephalosporin
6.3.1.2. Penicillin
6.3.1.3. Macrolide
6.3.2. Surgery
6.3.2.1. Endoscopy
6.3.2.2. Balloon Sinusplasty
6.3.3. Analgesics
6.3.4. Antihistamines
6.3.5. Corticosteroids
6.3.6. Sulphonamides
6.3.7. Quinolones
6.4. Market Attractiveness Analysis, by Treatment
7. Global Sinusitis Treatment Market Analysis and Forecast, by Disease
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease, 2017–2031
7.3.1. Acute Sinusitis
7.3.2. Sub-acute Sinusitis
7.3.3. Chronic Sinusitis
7.4. Market Attractiveness Analysis, by Disease
8. Global Sinusitis Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Route of Administration, 2017–2031
8.3.1. Topical
8.3.2. Nasal
8.3.3. Oral
8.3.4. Injectable
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Sinusitis Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Online Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Hospital Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Sinusitis Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Sinusitis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Antibiotics
11.2.1.1. Cephalosporin
11.2.1.2. Penicillin
11.2.1.3. Macrolide
11.2.2. Surgery
11.2.2.1. Endoscopy
11.2.2.2. Balloon Sinusplasty
11.2.3. Analgesics
11.2.4. Antihistamines
11.2.5. Corticosteroids
11.2.6. Sulphonamides
11.2.7. Quinolones
11.3. Market Value Forecast, by Disease, 2017–2031
11.3.1. Acute Sinusitis
11.3.2. Sub-acute Sinusitis
11.3.3. Chronic Sinusitis
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Topical
11.4.2. Nasal
11.4.3. Oral
11.4.4. Injectable
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Online Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Hospital Pharmacies
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Disease
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Sinusitis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Antibiotics
12.2.1.1. Cephalosporin
12.2.1.2. Penicillin
12.2.1.3. Macrolide
12.2.2. Surgery
12.2.2.1. Endoscopy
12.2.2.2. Balloon Sinusplasty
12.2.3. Analgesics
12.2.4. Antihistamines
12.2.5. Corticosteroids
12.2.6. Sulphonamides
12.2.7. Quinolones
12.3. Market Value Forecast, by Disease, 2017–2031
12.3.1. Acute Sinusitis
12.3.2. Sub-acute Sinusitis
12.3.3. Chronic Sinusitis
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Topical
12.4.2. Nasal
12.4.3. Oral
12.4.4. Injectable
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Online Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Hospital Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Treatment
12.7.2. By Disease
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Sinusitis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Antibiotics
13.2.1.1. Cephalosporin
13.2.1.2. Penicillin
13.2.1.3. Macrolide
13.2.2. Surgery
13.2.2.1. Endoscopy
13.2.2.2. Balloon Sinusplasty
13.2.3. Analgesics
13.2.4. Antihistamines
13.2.5. Corticosteroids
13.2.6. Sulphonamides
13.2.7. Quinolones
13.3. Market Value Forecast, by Disease, 2017–2031
13.3.1. Acute Sinusitis
13.3.2. Sub-acute Sinusitis
13.3.3. Chronic Sinusitis
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Topical
13.4.2. Nasal
13.4.3. Oral
13.4.4. Injectable
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Online Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Hospital Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Treatment
13.7.2. By Disease
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Sinusitis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017–2031
14.2.1. Antibiotics
14.2.1.1. Cephalosporin
14.2.1.2. Penicillin
14.2.1.3. Macrolide
14.2.2. Surgery
14.2.2.1. Endoscopy
14.2.2.2. Balloon Sinusplasty
14.2.3. Analgesics
14.2.4. Antihistamines
14.2.5. Corticosteroids
14.2.6. Sulphonamides
14.2.7. Quinolones
14.3. Market Value Forecast, by Disease, 2017–2031
14.3.1. Acute Sinusitis
14.3.2. Sub-acute Sinusitis
14.3.3. Chronic Sinusitis
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Topical
14.4.2. Nasal
14.4.3. Oral
14.4.4. Injectable
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Online Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Hospital Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Treatment
14.7.2. By Disease
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Sinusitis Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment, 2017–2031
15.2.1. Antibiotics
15.2.1.1. Cephalosporin
15.2.1.2. Penicillin
15.2.1.3. Macrolide
15.2.2. Surgery
15.2.2.1. Endoscopy
15.2.2.2. Balloon Sinusplasty
15.2.3. Analgesics
15.2.4. Antihistamines
15.2.5. Corticosteroids
15.2.6. Sulphonamides
15.2.7. Quinolones
15.3. Market Value Forecast, by Disease, 2017–2031
15.3.1. Acute Sinusitis
15.3.2. Sub-acute Sinusitis
15.3.3. Chronic Sinusitis
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Topical
15.4.2. Nasal
15.4.3. Oral
15.4.4. Injectable
15.5. Market Value Forecast, by Distribution Channel, 2017–2031
15.5.1. Online Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Hospital Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Treatment
15.7.2. By Disease
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Share Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. Sun Pharmaceutical Industries, Inc.
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Product Portfolio
16.2.1.3. SWOT Analysis
16.2.1.4. Strategic Overview
16.2.2. Pfizer, Inc.
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Product Portfolio
16.2.2.3. SWOT Analysis
16.2.2.4. Strategic Overview
16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Product Portfolio
16.2.3.3. SWOT Analysis
16.2.3.4. Strategic Overview
16.2.4. Fresenius Kabi USA, LLC
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Product Portfolio
16.2.4.3. SWOT Analysis
16.2.4.4. Strategic Overview
16.2.5. Dr. Reddy's Laboratories, Inc.
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Product Portfolio
16.2.5.3. SWOT Analysis
16.2.5.4. Strategic Overview
16.2.6. Novartis AG
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Product Portfolio
16.2.6.3. SWOT Analysis
16.2.6.4. Strategic Overview
16.2.7. Teva Pharmaceutical Industries Ltd.
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Product Portfolio
16.2.7.3. SWOT Analysis
16.2.7.4. Strategic Overview
16.2.8. Sanofi
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Product Portfolio
16.2.8.3. SWOT Analysis
16.2.8.4. Strategic Overview
16.2.9. Abbott Laboratories
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Product Portfolio
16.2.9.3. SWOT Analysis
16.2.9.4. Strategic Overview
16.2.10. Bayer AG
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Product Portfolio
16.2.10.3. SWOT Analysis
16.2.10.4. Strategic Overview
16.2.11. Eli Lilly And Company
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Product Portfolio
16.2.11.3. SWOT Analysis
16.2.11.4. Strategic Overview
16.2.12. Bristol-Myers Squibb
16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.12.2. Product Portfolio
16.2.12.3. SWOT Analysis
16.2.12.4. Strategic Overview
16.2.13. Merck & Co, Inc.
16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.13.2. Product Portfolio
16.2.13.3. SWOT Analysis
16.2.13.4. Strategic Overview
16.2.14. AstraZeneca plc
16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.14.2. Product Portfolio
16.2.14.3. SWOT Analysis
16.2.14.4. Strategic Overview
16.2.15. Amneal Pharmaceuticals LLC
16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.15.2. Product Portfolio
16.2.15.3. SWOT Analysis
16.2.15.4. Strategic Overview
16.2.16. GlaxoSmithKline plc
16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.16.2. Product Portfolio
16.2.16.3. SWOT Analysis
16.2.16.4. Strategic Overview
16.2.17. Apotex, Inc.
16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.17.2. Product Portfolio
16.2.17.3. SWOT Analysis
16.2.17.4. Strategic Overview
16.2.18. Hikma Pharmaceuticals plc
16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.18.2. Product Portfolio
16.2.18.3. SWOT Analysis
16.2.18.4. Strategic Overview
16.2.19. Wockhardt
16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.19.2. Product Portfolio
16.2.19.3. SWOT Analysis
16.2.19.4. Strategic Overview
16.2.20. Mylan N.V.
16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.20.2. Product Portfolio
16.2.20.3. SWOT Analysis
16.2.20.4. Strategic Overview
List of Tables
Table 01: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 03: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, by Surgery, 2017–2031
Table 04: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 05: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017 2031
Table 06: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 08: North America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 09: North America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 10: North America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 11: North America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Surgery, 2017–2031
Table 12: North America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 13: North America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 14: North America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 15: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 17: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 18: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast, by Surgery, 2017–2031
Table 19: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 20: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 21: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 22: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 24: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 25: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast, by Surgery, 2017–2031
Table 26: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 27: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 28: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 29: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 30: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 31: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 32: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Surgery, 2017–2031
Table 33: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 34: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 35: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 36: Middle East & Africa Sinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 37: Middle East & Africa Sinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 38: Middle East & Africa Sinusitis Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 39: Middle East & Africa Sinusitis Treatment Market Value (US$ Mn) Forecast, by Surgery, 2017–2031
Table 40: Middle East & Africa Sinusitis Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 41: Middle East & Africa Sinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 42: Middle East & Africa Sinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Sinusitis Treatment Market Value Share, by Treatment, 2020
Figure 03: Global Sinusitis Treatment Market Value Share, by Disease, 2020
Figure 04: Global Sinusitis Treatment Market Value Share, by Distribution Channel, 2020
Figure 05: Global Sinusitis Treatment Market Value Share, by Region, 2020
Figure 06: Global Sinusitis Treatment Market Value Share, by Route of Administration, 2020
Figure 07: Global Sinusitis Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 08: Global Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 09: Global Sinusitis Treatment Market Value (US$ Mn), by Analgesics, 2017–2031
Figure 10: Global Sinusitis Treatment Market Value (US$ Mn), by Antihistamines, 2017–2031
Figure 11: Global Sinusitis Treatment Market Value (US$ Mn), by Corticosteroids, 2017–2031
Figure 12: Global Sinusitis Treatment Market Value (US$ Mn), by Antibiotics, 2017–2031
Figure 13: Global Sinusitis Treatment Market Value (US$ Mn), by Sulphonamides, 2017–2031
Figure 14: Global Sinusitis Treatment Market Value (US$ Mn), by Quinolones, 2017–2031
Figure 15: Global Sinusitis Treatment Market Value (US$ Mn), by Surgery, 2017–2031
Figure 16: Global Sinusitis Treatment Market Value Share Analysis, by Disease, 2020 and 2031
Figure 17: Global Sinusitis Treatment Market Attractiveness Analysis, by Disease, 2021–2031
Figure 18: Global Sinusitis Treatment Market Value (US$ Mn), by Acute Sinusitis, 2017–2031
Figure 19: Global Sinusitis Treatment Market Value (US$ Mn), by Sub-acute Sinusitis, 2017–2031
Figure 20: Global Sinusitis Treatment Market Value (US$ Mn), by Chronic Sinusitis, 2017–2031
Figure 21: Global Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 22: Global Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 23: Global Sinusitis Treatment Market Value (US$ Mn), by Topical, 2017–2031
Figure 24: Global Sinusitis Treatment Market Value (US$ Mn), by Nasal, 2017–2031
Figure 25: Global Sinusitis Treatment Market Value (US$ Mn), by Oral, 2017–2031
Figure 26: Global Sinusitis Treatment Market Value (US$ Mn), by Injectable, 2017–2031
Figure 27: Global Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 28: Global Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 29: Global Sinusitis Treatment Market Value (US$ Mn), by Online Pharmacies, 2017–2031
Figure 30: Global Sinusitis Treatment Market Value (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 31: Global Sinusitis Treatment Market Value (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 32: Global Sinusitis Treatment Market Value Share Analysis, by Region, 2020 and 2031
Figure 33: Global Sinusitis Treatment Market Attractiveness Analysis, by Region, 2021–2031
Figure 34: North America Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 35: North America Sinusitis Treatment Market Value Share, by Country/Sub-region, 2020–2031
Figure 36: North America Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 37: North America Sinusitis Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 38: North America Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 39: North America Sinusitis Treatment Market Value Share Analysis, by Disease, 2020 and 2031
Figure 40: North America Sinusitis Treatment Market Attractiveness Analysis, by Disease, 2021–2031
Figure 41: North America Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 42: North America Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 43: North America Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 44: North America Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 45: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 46: Europe Sinusitis Treatment Market Value Share, by Country/Sub-region, 2020–2031
Figure 47: Europe Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 48: Europe Sinusitis Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 49: Europe Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 50: Europe Sinusitis Treatment Market Value Share Analysis, by Disease, 2020 and 2031
Figure 51: Europe Sinusitis Treatment Market Attractiveness Analysis, by Disease, 2021–2031
Figure 52: Europe Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 53: Europe Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 54: Europe Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 55: Europe Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 56: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 57: Asia Pacific Sinusitis Treatment Market Value Share, by Country/Sub-region, 2020–2031
Figure 58: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 59: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 60: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 61: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Disease, 2020 and 2031
Figure 62: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Disease, 2021–2031
Figure 63: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 64: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 65: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 66: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 67: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 68: Latin America Sinusitis Treatment Market Value Share, by Country/Sub-region, 2020–2031
Figure 69: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 70: Latin America Sinusitis Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 71: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 72: Latin America Sinusitis Treatment Market Value Share Analysis, by Disease, 2020 and 2031
Figure 73: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Disease, 2021–2031
Figure 74: Latin America Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 75: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 76: Latin America Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 77: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 78: Middle East & Africa Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 79: Middle East & Africa Sinusitis Treatment Market Value Share, by Country/Sub-region, 2020–2031
Figure 80: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 81: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 82: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 83: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Disease, 2020 and 2031
Figure 84: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Disease, 2021–2031
Figure 85: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 86: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 87: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 88: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 89: Global Sinusitis Treatment Market Share, by Company, 2020
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes